TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00983957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-790052
Description: Tablets, Oral, 60 mg, once daily, 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ortho Tri-Cyclen®
Description: Tablets, Oral, once daily, 78 days
Study: NCT03268161

Intervention type: DIAGNOSTIC_TEST
Intervention: Mutational analysis of clonal B cells
Description: Mutational analysis based on medullary or blood samples stored in a bio-bank during routine lymphocyte phenotyping.~Mutations affecting MYD88 (MYD88 L265P mutation), CXCR4 (Whim-like CXCR4 mutation) loci are sought.
Study: NCT00421733

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zemplar (paricalcitol ) capsules
Description: Group 2 - paricalcitol 1 mcg capsules once daily (one paricalcitol 1 mcg capsule once daily and one matching placebo capsule once daily)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zemplar (paricalcitol) capsules
Description: Group 3 - paricalcitol 2 mcg capsules once daily (two paricalcitol 1 mcg capsules once daily)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Group 1 - Placebo once daily (two placebo capsules once daily)
Study: NCT03848351

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Oral Hygiene Instruction (OHI)
Description: OHI will be given focusing on electric toothbrushing as first instance and subsequently focusing on interdental cleaning. OHI will be delivered by trained dental hygienist/periodontist. In the first phase the clinician will explain and show the technique to the patient. The patient will be then invited to perform the technique. Each phase will be assisted and monitored by the clinician. Overall, this sequence may be repeated as many times as the clinician would deem appropriate.
Study: NCT01992159

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection
Study: NCT01146210

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03328026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: retifanlimab
Description: retifanlimab 375mg administered as an intravenous infusion over 30-60 minutes every 3 weeks per randomization
Study: NCT03848351

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Professional supragingival scaling and polishing
Description: Patients will receive a session of professional supragingival scaling and polishing, that consists of removal of dental plaque and dental calculus from the surface of a tooth, with great care in performing exclusively coronal maneuver. No instrumentation or exploring of the gingival crevice/ sulcus will be performed. Instrumentation will be performed by a trained dental hygienist/periodontist.
Study: NCT02157051

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine
Description: Given ID

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine
Description: Given ID

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine
Description: Given ID

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine
Description: Given ID

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03492138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC201
Description: 625mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Dose to be determined in Phase 1 of study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40mg
Study: NCT03413423

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BAT-CS
Description: All participants will receive one hour standard smoking cessation counseling during their hospitalization for an acute coronary syndrome. Participants will be randomized 1 week after discharge. Those assigned to BAT-CS condition will receive 5 more counseling sessions over the 12 weeks after discharge. The first will be up to one hour and will be conducted in person. The next 4 sessions will occur by phone and will take about 30 minutes. Post-discharge sessions will be focused on smoking cessation and mood management using behavioral activation techniques. Participants will be offered the nicotine patch if medically cleared.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation and Health & Wellness
Description: All participants will receive one hour of standard smoking cessation counseling during their hospitalization for an acute coronary syndrome. Participants will be randomized 1 week after discharge. Those assigned to the Smoking Cessation plus Health and Wellness condition will receive 5 more counseling sessions over the 12 weeks after hospital discharge. The first will be up to one hour and will be conducted in person. The next 4 sessions will occur over the phone and will take about 30 minutes. Post-discharge sessions will be focused on smoking cessation and didactic health and wellness education. Participants will be offered the nicotine patch if medically cleared.
Study: NCT02722239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xigduo XR
Description: a single oral dose of modified release fixed dose combination film-coated tablet consisting of 10 mg dapagliflozin IR and 1000 mg metformin hydrochloride extended release

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xigduo XR
Description: a single oral dose of modified release fixed dose combination film-coated tablet consisting of 10 mg dapagliflozin IR and 1000 mg metformin hydrochloride extended release
Study: NCT03809546

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dronabinol
Description: THC (Marinol® \[dronabinol\]; Solvay Pharmaceuticals) will be orally administered in doses of 7.5 mg and 15 mg, in opaque capsules with dextrose filler. Placebo capsules contain only dextrose. These doses of THC are known to produce performance impairments as well as subjective intoxication with little to no adverse reactions in experienced occasional, but non-daily cannabis users (Ménétrey et al., 2005; Issa et al. 2016).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dronabinol
Description: THC (Marinol® \[dronabinol\]; Solvay Pharmaceuticals) will be orally administered in doses of 7.5 mg and 15 mg, in opaque capsules with dextrose filler. Placebo capsules contain only dextrose. These doses of THC are known to produce performance impairments as well as subjective intoxication with little to no adverse reactions in experienced occasional, but non-daily cannabis users (Ménétrey et al., 2005; Issa et al. 2016).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dextrose
Description: We are administering dextrose to health volunteers for our placebo group
Study: NCT01613235

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Induced hypertension
Description: Blood pressure will be raised in order to improve cerebral blood flow (CBF). In case of a low cardiac output, inotropics will be added. Induced hypertension will be continued for at least 48 hours when patients show some improvement within the first 24 hours. After 48 hours, the dose of vasopressor will be tapered daily, and resumed in case of clinical deterioration. In patients who do not show any improvement within 24 hours, induced hypertension will not be continued.
Study: NCT02762864

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: platelet (P2Y12) reaction units
Description: VerifyNow P2Y12 assay point-of-care testing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: platelet (P2Y12) reaction units
Description: VerifyNow P2Y12 assay point-of-care testing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Description: Antiplatelet therapy approved for ACS. Antagonist of P2Y12 and inhibitor of adenosine diphosphate (ADP)-induced platelet aggregation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator
Description: dual antiplatelet therapy with clopidogrel 75 mg and aspirin 100 mg daily will be continued for 6 months after the procedure for patient followed with single antiplatelet therapy with clopidogrel 75 mg daily throughout the follow-up period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator
Description: dual antiplatelet therapy with clopidogrel 75 mg and aspirin 100 mg daily will be continued for 6 months after the procedure for patient followed with single antiplatelet therapy with clopidogrel 75 mg daily throughout the follow-up period.
Study: NCT01223248

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IGIMRT using a single dose of 24 Gy
Description: Pts in both the hypofractionated \& single dose arms will receive the same following standard procedures. The only difference between the arms is the dose delivered at each treatment. 20 MSKCC pts (10 per treatment arm) will be accrued to undergo baseline DW-MRI \& DCE-MRI pretreatment for both arms \& 1 hour after their initial treatment for single fraction pts, \& within one hour of their initial \& final radiation treatment for the hypofractionated pts. Pts will be considered for this scan based on compliance to scan schedule \& MRI availability for performing the scan within one hour of the planned IGRT. 24 MSKCC pts (12 per treatment arm) will be accrued for the blood collection (optional) up to 4 hours prior, 50-90 minutes after, \& approximately 24 hours \[MCPG2.3\]after treatment for single fraction pts. For pts partaking in both sub-studies, the post-treatment blood collection may be done in a 50-120 minute window to account for scheduling conflicts with the research MRI.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IGIMRT 27 Gy in 3 fractions
Description: Pts in both the hypofractionated \& single dose arms will receive the same following standard procedures. The only difference between the arms is the dose delivered at each treatment. 20 MSKCC pts (10 per treatment arm) will be accrued to undergo baseline DW-MRI \& DCE-MRI pretreatment for both arms \& within 1 hour after their initial treatment for single fraction pts, \& within one hour of their initial \& final radiation treatment for the hypofractionated pts. Pts will be considered for this scan based on compliance to scan schedule \& MRI availability for performing the scan within one hour of the planned IGRT. 24 MSKCC pts (12 per treatment arm) will be accrued for the blood collection (optional) up to 4 hours prior, 50-90 minutes after, \& approximately 24 hours \[MCPG2.3\]after treatment for single fraction pts. For pts partaking in both sub-studies, the post-treatment blood collection may be done in a 50-120 minute window to account for scheduling conflicts with the research MRI.
Study: NCT04382261

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing
Description: Full mouth or quadrant SRP

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Scaling and root planing
Description: Full mouth or quadrant SRP
Study: NCT03463317

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CE-mark approved LAA closure devices
Description: LAA closure with post procedure treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Description: post procedure treatment according to the physicians (recommendation are made in the protocol); oral anticoagulation is not prescribed in this group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: post procedure treatment according to the physicians (recommendation are made in the protocol); oral anticoagulation is not prescribed in this group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran
Description: Patients allocated to the best medical care group receive either NOAC therapy or VKA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: Patients allocated to the best medical care group receive either NOAC therapy or VKA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: Patients allocated to the best medical care group receive either NOAC therapy or VKA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Edoxaban
Description: Patients allocated to the best medical care group receive either NOAC therapy or VKA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenprocoumon
Description: Patients allocated to the best medical care group receive either NOAC therapy or VKA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Patients allocated to the best medical care group receive either NOAC therapy or VKA
Study: NCT00345371

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate
Study: NCT02722239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin ER (Glucophage® long)
Description: co-administration of a single oral dose of 10 mg dapagliflozin film-coated tablet (Forxiga™) and two tablets 500 mg metformin hydrochloride extended release tablets (Glucophage® long).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin ER (Glucophage® long)
Description: co-administration of a single oral dose of 10 mg dapagliflozin film-coated tablet (Forxiga™) and two tablets 500 mg metformin hydrochloride extended release tablets (Glucophage® long).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (Forxiga)
Description: co-administration of a single oral dose of 10 mg dapagliflozin film-coated tablet (Forxiga™) and two tablets 500 mg metformin hydrochloride extended release tablets (Glucophage® long).
Study: NCT01277731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Run-in period: dexamethasone 10-20mg q day iv during chemotherapy Treatment period: methylprednisolone 60-125mg iv during chemotherapy
Study: NCT01151631

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: occipital nerve stimulation
Description: Low occipital bilateral Quad Plus, midline to laterally directed, secured by titan anchors, connected to Versitrel. No trial stimulation. Suggested stimulation parameters: Pulse width: 450, Amplitude: protocol, Rate: 60

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: occipital nerve stimulation
Description: Low occipital bilateral Quad Plus, midline to laterally directed, secured by titan anchors, connected to Versitrel. No trial stimulation. Suggested stimulation parameters: Pulse width: 450, Amplitude: protocol, Rate: 60
Study: NCT03725735

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for problem gambling with emotion regulation
Description: CBT group treatment for problem gambling with emotion regulation focus, with 8 sessions.
Study: NCT01368731

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prophylactic use of coagulation therapy
Description: The procedure is completed as per usual, and if the patient has been randomized to the intervention group the appropriate coagulation therapy will be applied immediately after standard EMR to visible vessels within the mucosal resection area.
Study: NCT02774720

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Centre-based exercise
Description: Participants will come to a centre (University of Waterloo or Toronto Rehabilitation Institute) for a one-hour, small group exercise class each week. The classes will include progressive aerobic and resistance exercise. They will be prescribed additional exercise to be performed independently (either at home or in the community).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based exercise
Description: Participants will be prescribed aerobic and resistance exercise to be performed independently (either at home or in the community). They will receive monthly phone calls to discuss achievements and barriers and to tje adjust exercise prescription.
Study: NCT02669277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIG prepared by minipool technology
Description: Drug: To demonstrate the efficacy of new product IVIG prepared by minipool technology as assessed by Bleeding Score and platelet count at 3 days, 1 week, 2 weeks and 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard IVIG product
Description: to compare efficacy and safety with the minipool IVIG
Study: NCT03607643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: * Sublingual dose of 1 mL (0.910 g) of BRCX014 in the morning, prior to the first meal of the day~* Sublingual dose of 1 mL (0.910 g) of BRCX014 in the afternoon, prior to the evening meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: * Sublingual dose of 1 mL (0.910 g) of BRCX014 in the morning, prior to the first meal of the day~* Sublingual dose of 1 mL (0.910 g) of BRCX014 in the afternoon, prior to the evening meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: * Sublingual dose of 1 mL (0.910 g) of BRCX014 in the morning, prior to the first meal of the day~* Sublingual dose of 1 mL (0.910 g) of BRCX014 in the afternoon, prior to the evening meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: * Sublingual dose of 1 mL (0.910 g) of BRCX014 in the morning, prior to the first meal of the day~* Sublingual dose of 1 mL (0.910 g) of BRCX014 in the afternoon, prior to the evening meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: * Sublingual dose of 1 mL (0.910 g) of BRCX014 in the morning, prior to the first meal of the day~* Sublingual dose of 1 mL (0.910 g) of BRCX014 in the afternoon, prior to the evening meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Standard of care (SOC) chemotherapy for multiple myeloma will include a bortezomib-based regimen given at 1.3 mg/m2 on days 1, 4, 8 \& 11 schedule to be repeated every 21 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bortezomib
Description: Standard of care (SOC) chemotherapy for multiple myeloma will include a bortezomib-based regimen given at 1.3 mg/m2 on days 1, 4, 8 \& 11 schedule to be repeated every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Leucovorin
Description: Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
Study: NCT02334410

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole body vibration (WBV)
Description: Side-alternating WBV
Study: NCT01408329

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CVAC Device (Cyclic Variations in Altitude Conditioning)
Description: A hypobaric hypoxia chamber

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CVAC Device (Cyclic Variations in Altitude Conditioning)
Description: A hypobaric hypoxia chamber
Study: NCT01186497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium: Treatment E
Description: The contents of 2 rabeprazole sprinkle capsules equivalent to 10 mg rabeprazole sodium mixed with a tablet vehicle suspension (Treatment E) on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium: Treatment E
Description: The contents of 2 rabeprazole sprinkle capsules equivalent to 10 mg rabeprazole sodium mixed with a tablet vehicle suspension (Treatment E) on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium: Treatment E
Description: The contents of 2 rabeprazole sprinkle capsules equivalent to 10 mg rabeprazole sodium mixed with a tablet vehicle suspension (Treatment E) on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium: Treatment E
Description: The contents of 2 rabeprazole sprinkle capsules equivalent to 10 mg rabeprazole sodium mixed with a tablet vehicle suspension (Treatment E) on Day 1.
Study: NCT00345371

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Study: NCT02604719

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic Acid and Ethamsylate
Description: The intervention will be the intravenous administration of 10 ml blinded vial of the study drugs (either 1 gmTranexamic acid and 1 gm Ethamsylate or placebo according to randomization group) slowly (over 30-60 sec ) in the 2 minutes after birth and the routine prophylactic oxytocin and after the cord has been clamped , all generally by the anesthesiologist or obstetrician then a pad will be placed under women buttocks then weighting the pads to allow objective measurement of blood loss.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid and Ethamsylate
Description: The intervention will be the intravenous administration of 10 ml blinded vial of the study drugs (either 1 gmTranexamic acid and 1 gm Ethamsylate or placebo according to randomization group) slowly (over 30-60 sec ) in the 2 minutes after birth and the routine prophylactic oxytocin and after the cord has been clamped , all generally by the anesthesiologist or obstetrician then a pad will be placed under women buttocks then weighting the pads to allow objective measurement of blood loss.
Study: NCT04049188

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Single-Fraction Palliative Radiation Therapy
Description: All subjects will be undergo single-fraction palliative radiation therapy who have cancer and associated bone metastases and symptomatic bone pain.
Study: NCT00059761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study: NCT01186497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium: Treatment E
Description: The contents of 2 rabeprazole sprinkle capsules equivalent to 10 mg rabeprazole sodium mixed with a tablet vehicle suspension (Treatment E) on Day 1.
Study: NCT01512537

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Narrowband UVB
Description: UVB 3 times a week